ALNY News and Press, Alnylam Pharmaceuticals Inc. From 11/08/21

Alnylam Pharmaceuticals (NASDAQ:ALNY) announces the initiation of a global Phase 2 study to evaluate the efficacy and safety of zilebesiran (formerly known as ALN-AGT), which is being developed as a treatment for hypertension. The trial will evaluate the efficacy and safety of zilebesira...

– KARDIA-2 will Evaluate Efficacy and Safety of Zilebesiran when Used in Combination with Conventional Antihypertensive Medications – Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), the leading RNAi therapeutics company, today announced initiation of KARDIA-2...

- Lumasiran Resulted in Substantial Reductions in Plasma Oxalate in PH1 Patients with Severe Renal Impairment - Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), the leading RNAi therapeutics company, announced today positive results from the 6-month primary analysis of the ...

– Annual survey has ranked Alnylam within the top five on the best employers list since 2019 – Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), the leading RNAi therapeutics company, announced today that it has ranked third in Science’s 2021 Top Emp...

Cantor Fitzgerald reiterated the overweight rating on Alnylam Pharmaceuticals (ALNY -1.6%) even after the company shares tanked on Thursday amid concerns over the departure of its founding CEO John Maraganore after 19-years at the helm. As the announcement coincided with worse than expec...

Image source: The Motley Fool. Alnylam Pharmaceuticals, inc (NASDAQ: ALNY) Q3 2021 Earnings Call Oct 29, 2021 , 8:30 p.m. ET Operator Continue reading For further details see: Alnylam Pharmaceuticals, inc (ALNY) Q3 2021 Earnings Call Tran...

Shares of Alnylam Pharmaceuticals (NASDAQ: ALNY) are tanking this week, falling 18.4% as of the market close on Thursday, according to data from S&P Global Market Intelligence . The decline came primarily after the company announced its third-quarter results on Thursday...

Alnylam Pharmaceuticals, Inc. (ALNY) Q3 2021 Earnings Conference Call October 28, 2021 08:30 ET Company Participants Christine Lindenboom - Investor Relations John Maraganore - Chief Executive Officer Yvonne Greenstreet - President & Chief Operating Officer Tolga Tanguler - Chief Commerci...

The following slide deck was published by Alnylam Pharmaceuticals, Inc. in conjunction with their 2021 Q3 earnings call. For further details see: Alnylam Pharmaceuticals, Inc. 2021 Q3 - Results - Earnings Call Presentation

Gainers: HCW Biologics (NASDAQ:HCWB) +132%. InflaRx (NASDAQ:IFRX) +45%. Digital Brands Group (NASDAQ:DBGI) +43%. Lucid Group (NASDAQ:LCID) +38%. Wolfspeed (NASDAQ:WOLF) +32%. LendingClub Corporation (NYSE:LC) +32%. Overstock (NASDAQ:OSTK) +25%. Impinj (NASDAQ:PI) +24%. Triterras (NASDAQ:TRIT)...